NCT02826772View on ClinicalTrials.gov

Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 10, 2016

Primary Completion Date

May 15, 2019

Study Completion Date

February 15, 2020

Conditions

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Interventions

DRUG

GT0918

anti-tumor activity

Trial Locations (6)

11733

North Shore Hematology Oncology Associates, East Setauket

21204

Chesapeake Urology Research Associates, Towson

44718

Gabrail Cancer Center Research, Canton

68130

G U Research Network, Omaha

89169

Comprehensive Cancer Centers of Nevada, Las Vegas

08901

Rutgers University, New Brunswick

All Listed Sponsors

lead

Suzhou Kintor Pharmaceutical Inc,

INDUSTRY

NCT02826772 - Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer | Biotech Hunter | Biotech Hunter